AMLX logo

Amylyx Pharmaceuticals (AMLX) Company Overview

Profile

Full Name:

Amylyx Pharmaceuticals, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

January 7, 2022

Indexes:

Not included

Description:

Amylyx Pharmaceuticals focuses on developing innovative treatments for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The company aims to improve patients' quality of life through its unique therapies, combining scientific research with a commitment to addressing unmet medical needs in the field of neurology.

Key Details

Price

$3.84

Annual Revenue

$380.79 M(+1612.94% YoY)

Annual EPS

$0.70(+120.65% YoY)

Beta

2.06

Events Calendar

Earnings

Next earnings date:

Feb 21, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Feb 22, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 5, 24 HC Wainwright & Co.
Buy
Nov 18, 24 Baird
Outperform
Nov 8, 24 HC Wainwright & Co.
Buy
Oct 18, 24 HC Wainwright & Co.
Buy
Jul 12, 24 Goldman Sachs
Neutral
Jul 10, 24 HC Wainwright & Co.
Buy
Jun 24, 24 HC Wainwright & Co.
Buy
May 14, 24 Mizuho
Neutral
May 10, 24 HC Wainwright & Co.
Buy
Apr 11, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation
AMLX
accessnewswire.comFebruary 5, 2025

NEW YORK CITY, NY / ACCESS Newswire / February 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out
AMLX
accessnewswire.comFebruary 4, 2025

NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
AMLX
accessnewswire.comFebruary 2, 2025

NEW YORK CITY, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock?
Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock?
Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock?
AMLX
zacks.comJanuary 31, 2025

Amylyx Pharmaceuticals (AMLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
AMLX
accesswire.comJanuary 13, 2025

NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation
AMLX
accesswire.comJanuary 12, 2025

NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
AMLX
businesswire.comJanuary 9, 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Amylyx. In addition, Amylyx intends to grant the underwriter a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the public offering at the public offering price per share, less underwriting.

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
AMLX
accesswire.comJanuary 7, 2025

NEW YORK CITY, NY / ACCESSWIRE / January 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect
AMLX
accesswire.comJanuary 6, 2025

NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation
AMLX
accesswire.comJanuary 5, 2025

NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

FAQ

  • What is the ticker symbol for Amylyx Pharmaceuticals?
  • Does Amylyx Pharmaceuticals pay dividends?
  • What sector is Amylyx Pharmaceuticals in?
  • What industry is Amylyx Pharmaceuticals in?
  • What country is Amylyx Pharmaceuticals based in?
  • When did Amylyx Pharmaceuticals go public?
  • Is Amylyx Pharmaceuticals in the S&P 500?
  • Is Amylyx Pharmaceuticals in the NASDAQ 100?
  • Is Amylyx Pharmaceuticals in the Dow Jones?
  • When was Amylyx Pharmaceuticals's last earnings report?
  • When does Amylyx Pharmaceuticals report earnings?
  • Should I buy Amylyx Pharmaceuticals stock now?

What is the ticker symbol for Amylyx Pharmaceuticals?

The ticker symbol for Amylyx Pharmaceuticals is NASDAQ:AMLX

Does Amylyx Pharmaceuticals pay dividends?

No, Amylyx Pharmaceuticals does not pay dividends

What sector is Amylyx Pharmaceuticals in?

Amylyx Pharmaceuticals is in the Healthcare sector

What industry is Amylyx Pharmaceuticals in?

Amylyx Pharmaceuticals is in the Biotechnology industry

What country is Amylyx Pharmaceuticals based in?

Amylyx Pharmaceuticals is headquartered in United States

When did Amylyx Pharmaceuticals go public?

Amylyx Pharmaceuticals's initial public offering (IPO) was on January 7, 2022

Is Amylyx Pharmaceuticals in the S&P 500?

No, Amylyx Pharmaceuticals is not included in the S&P 500 index

Is Amylyx Pharmaceuticals in the NASDAQ 100?

No, Amylyx Pharmaceuticals is not included in the NASDAQ 100 index

Is Amylyx Pharmaceuticals in the Dow Jones?

No, Amylyx Pharmaceuticals is not included in the Dow Jones index

When was Amylyx Pharmaceuticals's last earnings report?

Amylyx Pharmaceuticals's most recent earnings report was on Nov 7, 2024

When does Amylyx Pharmaceuticals report earnings?

The next expected earnings date for Amylyx Pharmaceuticals is Feb 21, 2025

Should I buy Amylyx Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions